280 related articles for article (PubMed ID: 26186022)
1. CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy.
Kranz LM; Birtel M; Krienke C; Grunwitz C; Petschenka J; Reuter KC; van de Roemer N; Vascotto F; Vormehr M; Kreiter S; Diken M
Hum Vaccin Immunother; 2016; 12(1):213-21. PubMed ID: 26186022
[No Abstract] [Full Text] [Related]
2. CIMT 2013: advancing targeted therapies--report on the 11th Annual Meeting of the Association for Cancer Immunotherapy, May 14-16 2013, Mainz, Germany.
Diken M; Attig S; Grunwitz C; Kranz L; Simon P; van de Roemer N; Vascotto F; Kreiter S
Hum Vaccin Immunother; 2013 Sep; 9(9):2025-32. PubMed ID: 23877042
[TBL] [Abstract][Full Text] [Related]
3. CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.
Kranz LM; Beck JD; Grunwitz C; Hotz C; Vormehr M; Diken M
Hum Vaccin Immunother; 2017 Oct; 13(10):2272-2279. PubMed ID: 28846471
[No Abstract] [Full Text] [Related]
4. CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.
Diken M; Boegel S; Grunwitz C; Kranz LM; Reuter K; van de Roemer N; Vascotto F; Vormehr M; Kreiter S
Hum Vaccin Immunother; 2014; 10(10):3090-100. PubMed ID: 25483671
[No Abstract] [Full Text] [Related]
5. The right patient for the right therapy: 13th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 11-13, 2015.
Miller M; Jahndel V; Kutscher S; Mahr A; Rae R; Kloke BP
Cancer Immunol Immunother; 2016 Oct; 65(10):1277-87. PubMed ID: 27259506
[No Abstract] [Full Text] [Related]
6. CIMT 2019: report on the 17th Annual Meeting of the Association for Cancer Immunotherapy.
Beck JD; Birtel M; Haefner E; Keil IS; Reidenbach D; Salomon N; Yildiz IG; Diken M
Hum Vaccin Immunother; 2020 Apr; 16(4):808-815. PubMed ID: 31584850
[No Abstract] [Full Text] [Related]
7. Mechanisms of efficacy in cancer immunotherapy: 14th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 10-12, 2016.
Theelen J; Braun J; Hörzer H; Kloke BP; Ott M; Pizzitola I; Schirmer U; Miller M
Cancer Immunol Immunother; 2017 May; 66(5):673-681. PubMed ID: 28251274
[No Abstract] [Full Text] [Related]
8. CIMT 2016: Mechanisms of efficacy in cancer immunotherapy - Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10-12 2016, Mainz, Germany.
Kranz LM; Birtel M; Hilscher L; Grunwitz C; Petschenka J; Vascotto F; Vormehr M; Voss RH; Kreiter S; Diken M
Hum Vaccin Immunother; 2016 Nov; 12(11):2805-2812. PubMed ID: 27435168
[No Abstract] [Full Text] [Related]
9. Toward next-generation cancer immunotherapy: 10th annual meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 23-25, 2012.
Kloke BP; Kutscher S; Rae R; Kvistborg P; Britten CM; Hadrup SR
Cancer Immunol Immunother; 2013 May; 62(5):975-81. PubMed ID: 23299564
[No Abstract] [Full Text] [Related]
10. CIMT 2018: Pushing frontiers in cancer immunotherapy - Report on the 16
Beck J; Birtel M; Reidenbach D; Salomon N; Diken M
Hum Vaccin Immunother; 2018; 14(12):2864-2873. PubMed ID: 30111232
[TBL] [Abstract][Full Text] [Related]
11. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
12. Cancer neoantigen: Boosting immunotherapy.
Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
[TBL] [Abstract][Full Text] [Related]
13. Personalized cancer neoantigen vaccines come of age.
Chu Y; Liu Q; Wei J; Liu B
Theranostics; 2018; 8(15):4238-4246. PubMed ID: 30128050
[TBL] [Abstract][Full Text] [Related]
14. CIMT 2022: Report on the 19th Annual Meeting of the Association for Cancer Immunotherapy.
Berger PA; Freitag J; Linkenbach SC; Merz L; Schork M; Thevissen S; Yildiz I; Beck JD
Hum Vaccin Immunother; 2022 Nov; 18(6):2124785. PubMed ID: 36222759
[TBL] [Abstract][Full Text] [Related]
15. Personalized vaccination against ovarian cancer: what are the possibilities?
Tanyi JL; George E
Expert Rev Vaccines; 2018 Nov; 17(11):955-958. PubMed ID: 30362844
[No Abstract] [Full Text] [Related]
16. CIMT 2021: report on the 18th Annual Meeting of the Association for Cancer Immunotherapy.
Billmeier A; Khinvasara K; Lang F; Mohr J; Reidenbach D; Schork M; Yildiz I; Diken M
Hum Vaccin Immunother; 2022 Dec; 18(1):2024416. PubMed ID: 35130105
[TBL] [Abstract][Full Text] [Related]
17. Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.
Gatti-Mays ME; Redman JM; Collins JM; Bilusic M
Hum Vaccin Immunother; 2017 Nov; 13(11):2561-2574. PubMed ID: 28857666
[TBL] [Abstract][Full Text] [Related]
18. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6-8, 2014.
Kloke BP; Mahr A; Jabulowsky RA; Kutscher S; Rae R; Britten CM
Cancer Immunol Immunother; 2015 Jul; 64(7):923-30. PubMed ID: 25548093
[No Abstract] [Full Text] [Related]
20. Personalized vaccines for cancer immunotherapy.
Sahin U; Türeci Ö
Science; 2018 Mar; 359(6382):1355-1360. PubMed ID: 29567706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
